Thinking About Medical Device Development Strategy in a Time of COVID-19

Ilisa Halpern Paul, president of the District Policy Group, and Partner Amy Judge-Prein and Associate Reed Abrahamson, discussed the importance of reimbursement strategy for emerging medical device companies, including measures companies can take ahead of FDA approval to promote a smooth coverage and reimbursement process and the ins and outs of Medicare reimbursement for medical device clinical trials. In addition, they provided best practices for planning and executing clinical trials during COVID-19.